Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 26
1.
Eur Rev Med Pharmacol Sci ; 26(4): 1131-1137, 2022 Feb.
Article En | MEDLINE | ID: mdl-35253168

OBJECTIVE: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. PATIENTS AND METHODS: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. RESULTS: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. CONCLUSIONS: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies.


Castleman Disease , Castleman Disease/diagnosis , Castleman Disease/pathology , Castleman Disease/therapy , Female , Humans , Lymph Nodes/pathology , Male , Prospective Studies , Retrospective Studies , Turkey/epidemiology
2.
Genet Mol Res ; 15(3)2016 Sep 09.
Article En | MEDLINE | ID: mdl-27706715

The aim of this study was to identify the possible correlation between polymorphisms in matrix metalloproteinase (MMP)-1 and MMP-3 and their corresponding protein levels in disc tissues obtained from patients with lumbar disc herniation (LDH) using biochemical and immunohistochemical analyses. Blood and disc samples were obtained from 100 patients with LDH who underwent a lumbar microdiscectomy. Based on the radiological degeneration, the patients were diagnosed with grade 2, 3, or 4 LDH. MMP-1 -1607 1G/2G and MMP-3 -1171 5A/6A were analyzed by real-time polymerase chain reaction. The expressions of MMP-1 and MMP- 3 were detected by biochemical and immunohistochemical analyses. We found no association between the MMP-1 polymorphism and disc degeneration and MMP-1 expression. However, patients expressing the 6A/6A and 5A/6A alleles of MMP-3 -11715A/6A showed higher MMP-3 expression, compared to those expressing the 5A/5A genotype. Additionally, the radiological degeneration grades were correlated with the histological degeneration scoring. Protein levels and immunopositive cell rates of MMP-1 and MMP-3 were associated with disc degeneration grades. Moreover, the MMP-1 and MMP-3 expression and the histological and radiological scores were positively correlated and the MMP-3 -11715A/6A polymorphism was associated with MMP-3 expression in herniated disc tissues. This study is the first to investigate polymorphisms in MMP-1 and MMP-3, as well as their corresponding protein expressions. We also quantified an association between the radiological degeneration grades and MMP-1 and MMP- 3 expression. Further genomic studies on MMPs could focus on the utilization of MMP-1 and MMP-3 as markers for the prevention and treatment of this disease.


Intervertebral Disc Degeneration/genetics , Intervertebral Disc Displacement/genetics , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 3/genetics , Polymorphism, Genetic , Adult , Aged , Alleles , Case-Control Studies , Genotype , Humans , Intervertebral Disc Degeneration/metabolism , Intervertebral Disc Degeneration/pathology , Intervertebral Disc Displacement/metabolism , Intervertebral Disc Displacement/pathology , Lumbar Vertebrae/metabolism , Lumbar Vertebrae/pathology , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 3/metabolism , Middle Aged
3.
Genet Mol Res ; 15(2)2016 Jun 03.
Article En | MEDLINE | ID: mdl-27323133

The etiology underlying neural tube defects (NTDs) is not fully understood and is believed to involve a complex milieu of genetic and environmental factors. The A1298C polymorphism in the methylenetetrahydropholate reductase gene (MTHFR) has been associated with mild risk for NTDs. In this study, the genotype distribution of the MTHFR gene A1298C polymorphism and the levels of serum homocysteine, vitamin B12, and folate were evaluated in 33 children with NTDs, their mothers, and 46 healthy controls. Genotyping of the A1298C polymorphism was performed by real-time polymerase chain reaction. The A and C allele frequencies in children with NTDs and their mothers were similar to controls (P = 0.160). The 1298AA and 1298CC genotype frequencies (P = 0.551 and 0.062, respectively) in children with NTDs and their mothers did not differ from controls. On the other hand, the 1298AC genotype frequencies in children with NTDs and their mothers were significantly different from controls (P = 0.025). The genotype frequency of 1298AC was lower in children with NTDs than in controls. There was no significant association between clinical distribution of NTDs and 1298AA/AC/CC genotypes (P > 0.05). Serum vitamin B12 levels were higher in children with NTDs than their mothers and controls (P = 0.001). There were no differences among serum homocysteine and folate levels in all groups (P = 0.494 and 0.141, respectively). Both genetic and nutritional factors are important in the etiology of NTDs. Thus, the A1298C polymorphism cannot be regarded as a major risk factor for NTDs.


Genetic Association Studies , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Neural Tube Defects/genetics , Adult , Child , Child, Preschool , Female , Gene Frequency , Genotype , Homocysteine/metabolism , Humans , Infant , Male , Neural Tube/pathology , Neural Tube Defects/blood , Neural Tube Defects/pathology , Risk Factors , Turkey , Vitamin B 12/blood
4.
Genet Couns ; 27(4): 519-524, 2016.
Article En | MEDLINE | ID: mdl-30226973

Polydactyly is among comnion extremity abnormalities. Mutations of GLI3 gene have been reported commonly in Greig Cephalopolysyndactyly Syndrome (GCPS) and Pallister-Hall Syndrome (PHS). We have determined two different mutations of GLI3 gene in two different cases, one of which is with GCPS and the other one is with PHS. A deletion mutation was detected in the proband with GCPS and his mother. Otherwise, we found that, unlike the previously reported, the mutation c.2437C>T, p.Q813X which was detected in the GLI3 gene caused typical PHS. We are in thought of that our cases will contribute to understanding of phenotypic variability leading to GLI3 mutations.


Acrocephalosyndactylia/genetics , DNA Mutational Analysis , Pallister-Hall Syndrome/genetics , Zinc Finger Protein Gli3/genetics , Acrocephalosyndactylia/diagnosis , Adolescent , Anus, Imperforate/diagnosis , Anus, Imperforate/genetics , Biological Variation, Population , Child , Genetic Carrier Screening , Genetic Counseling , Hamartoma/diagnosis , Hamartoma/genetics , Humans , Magnetic Resonance Imaging , Male , Pallister-Hall Syndrome/diagnosis , Pituitary Diseases/diagnosis , Pituitary Diseases/genetics , Sequence Deletion/genetics
5.
Genet Couns ; 27(2): 187-91, 2016.
Article En | MEDLINE | ID: mdl-29485809

Vohwinkel syndrome (VS), also known as keratoderma hereditaria mutilans, is a rare keratinization genetic disorder characterized by palmoplantar keratoderma, skeletal dysmorphisms and varying degrees of sensorineural deafness. Its mode of inheritance is autosomal-dominant, with mutations in loricrin and connexin 26 (GJB2) genes that manifest during infancy and boceme more evident during adulthood. We herein report a case of VS in a 23-year-old female exhibiting sensorineural hearing loss, palmar keratoderma and homozygous deletion mutation delE120 (c.358-360delGAG) in the GJB2 gene. VS, is a rare genetic disorder, should be considered in patients with palmoplantar keratoderma and hearing loss and should be investigated connexin 26 (GJB2) gene mutation.


Abnormalities, Multiple/genetics , Connexins/genetics , Hand Deformities, Congenital/genetics , Hearing Loss, Sensorineural/genetics , Keratoderma, Palmoplantar/genetics , Adult , Connexin 26 , Female , Humans , Sequence Deletion , Young Adult
6.
Transplant Proc ; 45(9): 3371-4, 2013 Nov.
Article En | MEDLINE | ID: mdl-24182818

OBJECTIVE: Serum albumin level is considered to be a marker reflecting the nutritional status in both healthy subjects and patients with malignancies. In this study we sought to investigate the association between pretransplantation serum albumin levels and prognosis among patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). METHODS: We retrospectively analyzed the data of 102 patients who underwent alloHSCT from 2004 to 2010. Pretransplant serum albumin, D-dimer, creatinine, and fibrinogen levels drawn within 10 days before transplantation were obtained from patient files. All parameters were divided into 2 groups: normal levels (group 1) versus abnormal levels (group 2). Our normal range of serum albumin is 3.2-5.2 g/dL; patients with pretransplantation albumin level ≥3.2 g/dL were included in group 1 versus group 2 with <3.2 g/dL. RESULTS: The patients included 42 (41.1%) female and 60 (58.9%) male patients. The diagnoses were acute myeloblastic leukemia in 65 (63.7%) and acute lymphoblastic leukemia in 37 (36.3%). The median age was 26.0 years (range, 13-57). Univariate and multivariate analysis showed that patients with serum albumin levels <3.2 g/dL experienced significantly lower overall survival (OS) compared with ≥3.2 g/dL (hazard ratio [HR] 2.32 [range, 1.23-4.54] and HR 2.70 [range 1.38-5.26], respectively; P = .009). The median (range) OS in group 2 was 230.0 (184.0-544.0) days versus 570.5 (249.5-1,101.0) days in group 1 (P = .007). For disease free survival (DFS) evaluation, univariate and multivariate analysis showed that patients with serum albumin levels <3.2 g/dL had significantly lower values compared with patients with serum albumin ≥3.2 g/dL. (HR 2.17 [range 0.98-4.76] and HR 2.85 [range, 1.25-6.66], respectively; P = .046). The median (range) DFS in group 2 was 184.0 (61.0-524.0) days versus 445.0 (199.0-917.5) days in group 1 (P = .045). Among the patient characteristics the presence of infection was a significant independent variable for worse OS (HR 2.12 [range, 0.98-4.36], P = .036). The other parameters-age, sex, donor status, time to transplant interval, conditioning regimens, HLA status, and number of total infused CD34(+) cells-showed no significant effect on OS and DFS (P = .05). CONCLUSIONS: Pretransplantation decreased serum albumin levels were associated with poor survival in patients with leukemia who underwent alloHSCT.


Hematopoietic Stem Cell Transplantation , Hypoalbuminemia/pathology , Nutritional Status , Adolescent , Adult , Female , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous , Young Adult
7.
J BUON ; 17(3): 490-6, 2012.
Article En | MEDLINE | ID: mdl-23033287

PURPOSE: To investigate the chromosomal aberrations in chronic myelogenous leukemia (CML), particularly in chromosomal regions which carried 67 genes pertaining to oncogenes, transcription factors, signal transduction, tumor suppressors, apoptosis etc, in addition to Philadelphia (Ph+) chromosome by multiplex ligation-dependent probe amplification (MLPA) method and to compare them with clinical parameters. METHODS: The aberrations were investigated in 48 CML patients receiving imatinib therapy and a group of 15 healthy controls, by using the MLPA method between 2000 and 2009. The obtained results were compared both between patient and control groups and with clinical parameters. RESULTS: Duplication was detected in the fibroblast growth factor receptor 1 (FGFR1) gene of 2 patients, inosine 5' monophosphate dehydrogenase 1 (IMPDH1) gene of 4, postmeiotic segregation increased S. Cerevisiae 2 (PMS2) gene of 1, nuclear factor kappa beta (NFKB) of 5 and T-cell translocation 2 (LMO2) gene of 1 patient. Univariate analysis showed that splenomegaly, advanced age, Sokal risk score (SRS) and the duplications in IMPDH1 and FGFR1 genes significantly shortened 7-year event-free survival (EFS); multivariate analysis showed that only the duplications in IMPDH1 and FGFR1 genes were the factors that significantly affected EFS. No statistically significant correlations were detected between duplications and other clinical parameters. CONCLUSION: Duplications in 4 genes (FGFR1, IMPDH1, PMS2, LMO2) in addition to Ph+ chromosome in CML patients were detected for the first time. This study indicates that chromosomes 7 and 8 should be particularly investigated in more detail in addition to the Ph+ chromosome for better determination of disease prognosis and selection of alternative treatments.


Chromosome Duplication , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Philadelphia Chromosome , Adenosine Triphosphatases/genetics , Adult , Aged , DNA Repair Enzymes/genetics , DNA-Binding Proteins/genetics , Female , Humans , IMP Dehydrogenase/genetics , Male , Middle Aged , Mismatch Repair Endonuclease PMS2 , Receptor, Fibroblast Growth Factor, Type 1/genetics
8.
Transplant Proc ; 44(6): 1764-6, 2012.
Article En | MEDLINE | ID: mdl-22841267

The demand for kidney transplantation due to improved recipient outcomes has stimulated surgeons to expand the criteria for usable donors, but still the use of organs from deceased donors with terminal acute renal failure is uncommon. We report 2 kidney transplant recipients from a cadaveric donor who was not accepted by other centers because of acute renal failure. The donor, a 24-year-old man with an intracerebral hemorrhage, displayed a serum creatinine (SCr) value of 0.6 mg/dL on hospital admission, which increased to 7.3 mg/dL on the fourth hospital day. After the diagnosis of brain death and refusal of the kidneys by other regional centers, we decided to transplant the 2 kidneys. Recipient 1, a 31-year-old man on an 11-year dialysis program, discontinued hemodialysis after 7 days of delayed graft function. The SCr level decreased gradually and was stable at 1.08 mg/dL on postoperative day (POD) 45. The contralateral graft was transplanted into a 30-year-old man (recipient 2) undergoing dialysis treatment for 7 years. After 10 days of delayed graft function, the SCr decreased gradually with continued hemodialysis until POD 24. The SCr level has been stable at 1.34 mg/dL on POD 52. At the end of the third month the SCr levels in recipients 1 and 2 were 1.1 mg/dL and 1.4 mg/dL, respectively. In conclusion, one may safely expand the donor pool with kidneys from deceased donors with acute renal failure (ARF) with good short-term outcomes.


Acute Kidney Injury/etiology , Donor Selection , Kidney Transplantation , Kidney Tubular Necrosis, Acute/etiology , Tissue Donors , Adult , Biomarkers/blood , Brain Death , Cadaver , Creatinine/blood , Delayed Graft Function/diagnosis , Delayed Graft Function/etiology , Delayed Graft Function/therapy , Humans , Kidney Transplantation/adverse effects , Male , Renal Dialysis , Time Factors , Treatment Outcome , Young Adult
9.
Neoplasma ; 59(2): 183-90, 2012.
Article En | MEDLINE | ID: mdl-22248276

Iron overload increases the risk of infections, veno-occlusive disease and hepatic dysfunction in post-transplant period. Our objective was to investigate the association of pre-transplant ferritin levels with complications and survival after allogeneic hematopoietic stem cell transplantation (alloHSCT).We retrospectively analysed 84 patients' data who had undergone allogeneic HSCT into two groups: patients with a serum ferritin level ≥ 1000 ng/ml, and patients with <1000 ng/ml at the time of HSCT.Cox-regression analysis showed that pre-transplant serum ferritin levels were significantly higher in patients who had at least one infectious event compared with those who had no any infectious event in the post-transplant 100 days (p<0.023). Overall survival (OS) and disease-free survival (DFS) rates were significantly higher in patients with a time-to-tx interval 12 months (p=0.002 and p=0.008 respectively). A higher risk of death was observed in high-ferritin group (hazard ratio=2.27, CI:1.01-5.09, p=0.023 for OS and hazard ratio=2.49, CI:1.12-5.53 p=0.039 for DFS). No significant effect on OS and DFS among groups was observed for variables conditioning regimen, gender and diagnosis. Acute GVHD was more common in patients with a ferritin level ≥ 1000 ng /mL, but this was not statistically significant (p>0.05). There was no statistical significance in both groups (ferritin ≥ 1000 ng /mL and ferritin <1000 ng/mL) for relapse rates (p>0.05). Platelet and neutrophil engaftment day was not found statistically significant compared with both groups (p=0.273 and p=0.882, respectively). Pre-transplant ferritin levels may predict poor outcomes in patients who had undergone allogeneic hematopoietic stem cell transplantation.


Biomarkers/blood , Ferritins/blood , Graft vs Host Disease/mortality , Hematologic Neoplasms/mortality , Hematopoietic Stem Cell Transplantation/adverse effects , Iron Overload/mortality , Adolescent , Adult , Female , Graft vs Host Disease/blood , Graft vs Host Disease/etiology , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Infections/blood , Infections/etiology , Iron Overload/blood , Iron Overload/etiology , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Transplantation Conditioning , Transplantation, Homologous , Young Adult
10.
Genet Mol Res ; 10(3): 1923-30, 2011 Aug 30.
Article En | MEDLINE | ID: mdl-21948754

We investigated a possible association between aggrecan gene polymorphism and lumbar degenerative disc disease in Turkish patients. One hundred 20-30-year-old patients with or without low back pain were selected for the study. Lumbar magnetic resonance imaging was performed on all patients. The patient group had low back pain clinically and degenerative disc disease radiographically. The control group included patients with and without low back pain: all were negative radiographically for degenerative disc disease. Genomic DNA was extracted from all participants. A PCR assay were used to evaluate variable number of tandem repeat polymorphism of aggrecan gene alleles to determine if there was any correlation with degenerative disc disease. Significant associations were found between short repeated alleles of the aggrecan gene and severe disc degeneration. A significant association was also found between short repeated alleles of the aggrecan gene and multilevel disc herniation as well as extrusion and sequestration types of disc herniation. In Turkish population, short repeated alleles of the aggrecan gene are associated with increased disc degeneration and disc herniation.


Aggrecans/genetics , Intervertebral Disc Degeneration/genetics , Intervertebral Disc Degeneration/pathology , Lumbar Vertebrae/pathology , Adult , Alleles , Extracellular Matrix/pathology , Female , Humans , Low Back Pain/genetics , Low Back Pain/pathology , Magnetic Resonance Imaging , Male , Minisatellite Repeats/genetics , Polymorphism, Single Nucleotide , Repetitive Sequences, Nucleic Acid , Turkey
11.
Osteoporos Int ; 22(4): 1219-25, 2011 Apr.
Article En | MEDLINE | ID: mdl-20532479

UNLABELLED: In this study, ERα gene PvuII and XbaI polymorphisms and COL1A1 gene Sp1 polymorphisms in postmenopausal women were compared with lumbar vertebra and femoral neck BMD values. In conclusion, it was designated that PvuII polymorphism was effective on average lumbar vertebra BMD value in postmenopausal women of our study group. INTRODUCTION: Bone mineral density (BMD), the major determinant of osteoporotic fracture risk, has a strong genetic component. Several candidate gene polymorphisms have been implicated in the regulation of this process. In this study, the relationship among BMD values of lumbar vertebra and femoral neck and ERα gene PvuII and XbaI polymorphisms and COL1A1 gene Sp1 polymorphism in 126 postmenopausal women (30 normal, 46 osteopenic, and 50 osteoporotic in terms of bone mineral density) was researched. METHODS: The ERα gene PvuII and XbaI genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) whereas the COL1A1 gene Sp1 genotype was determined by real-time PCR. BMDs at the lumbar spine (vertebrae L1-L4) and hip (femur neck) were measured by dual-energy X-ray absorptiometry. RESULTS: According to our study results, the significant difference was found in women with normal, osteopenic, and osteoporotic bone mass in terms of ERα gene PvuII polymorphism "pp" genotype frequency. The "pp" genotype frequency was significantly lower in women with normal bone mass. Average lumbar vertebra BMD value of women with "PP" genotype was significantly higher than that with "pp" genotype. On the other hand, in the evaluations on ERα gene XbaI polymorphism and COL1A1 gene Sp1 polymorphism, it was noted that there was no difference in terms of average BMD values, genotype, and allele frequencies among groups. CONCLUSION: In conclusion, it was designated that ERα gene PvuII polymorphism was effective on average lumbar vertebra BMD value in postmenopausal women of our study group.


Bone Density/genetics , Bone Diseases, Metabolic/genetics , Collagen Type I/genetics , Estrogen Receptor alpha/genetics , Bone Density/physiology , Bone Diseases, Metabolic/physiopathology , Collagen Type I, alpha 1 Chain , Female , Femur Neck/physiology , Femur Neck/physiopathology , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Lumbar Vertebrae/physiology , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/genetics , Osteoporosis, Postmenopausal/physiopathology , Polymerase Chain Reaction/methods , Polymorphism, Genetic , Polymorphism, Restriction Fragment Length , Postmenopause/genetics , Postmenopause/physiology
12.
Genet Mol Res ; 9(2): 1197-203, 2010 Jun 22.
Article En | MEDLINE | ID: mdl-20589617

Association between neural tube defects (NTDs) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in folate metabolism. Its deficiency usually leads to significant reductions in plasma concentrations of folate, vitamin B(12) and methionine, whereas homocysteine levels are increased. We examined folate, vitamin B(12) and homocysteine serum concentrations and polymorphism of the C677T MTHFR gene in Turkish children with neural tube defects. Thirty-three children with NTDs, 26 mothers and 48 healthy individuals were studied. C677T MTHFR polymorphism was determined by melting curve analyses (LightCycler). The levels of folate, vitamin B(12) and homocysteine serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the MTHFR gene. C677T allele frequencies in NTD children and their mothers were similar to those found in controls. Serum folate and vitamin B(12) concentrations were significantly higher in NTD children than that of controls. Serum homocysteine concentrations were not significantly higher in NTD children and mothers. We concluded that C677T MTHFR gene polymorphism does not affect folic acid, vitamin B(12) and homocysteine metabolism in Turkish children with NTDs. C677T polymorphism of the MTHFR gene cannot be regarded as a major risk factor for NTDs in Turkish children.


Folic Acid/metabolism , Genetic Predisposition to Disease , Homocysteine/metabolism , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Neural Tube Defects/etiology , Neural Tube Defects/genetics , Polymorphism, Genetic , Vitamin B 12/metabolism , Adult , Alleles , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Turkey
13.
Leuk Lymphoma ; 46(11): 1613-7, 2005 Nov.
Article En | MEDLINE | ID: mdl-16236615

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare tumor type distinct from classical Hodgkin lymphoma and its familial form is unusual. The two cases (mother at age 48 and son at age 30 years) of NLPHL in advanced clinical stage are described. The patients were successfully treated with an immunochemotherapy schedule consisting CHOP plus rituximab (CHOP-R). This chemotherapy was well tolerated and the patients reached complete remission. These remissions were for 34 and 40 months for mother and son, respectively. In patients with NLPHL, CHOP-R regimen should be used as an alternative treatment regimen to obtain a good long-lasting response without any adverse events.


Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Lymphocytes/pathology , Adult , Antibodies, Monoclonal, Murine-Derived , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Family Health , Female , Humans , Lymph Nodes/pathology , Male , Middle Aged , Prednisolone/therapeutic use , Remission Induction/methods , Rituximab , Vincristine/therapeutic use
14.
Ir J Med Sci ; 174(1): 33-6, 2005.
Article En | MEDLINE | ID: mdl-15868887

BACKGROUND: Solitary plasmacytoma localised to bone or soft tissue without myeloma. AIM: Clinical features and survival was analysed in patients from Central Anatolia. METHODS: Twenty-three solitary plasmacytoma (18 male, 5 female) were evaluated retrospectively. Median age was 58 years (46-72). The major localisation was vertebral column. RESULTS: All patients but one (larynx) had surgical resection and 21 patients received radiotherapy postoperatively. Multiple myeloma developed in eight patients (35%) and local relapse was detected in one patient. Eight patients died, causes of death were multiple myeloma progression in six patients, local relapse of intracranial plasmacytoma in one patient and cranial trauma in one patient who was in complete remission. Three and 5 years progression free survival were 45.6% and 22.8% respectively and overall survivals were 54.4% and 27.2% respectively. CONCLUSION: Solitary plasmacytoma cases should be followed carefully regarding local relapse and progression to myeloma.


Bone Neoplasms/pathology , Multiple Myeloma/secondary , Plasmacytoma/pathology , Soft Tissue Neoplasms/pathology , Bone Neoplasms/radiotherapy , Bone Neoplasms/surgery , Disease Progression , Female , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Plasmacytoma/radiotherapy , Plasmacytoma/surgery , Retrospective Studies , Soft Tissue Neoplasms/radiotherapy , Soft Tissue Neoplasms/surgery , Survival Analysis , Turkey
15.
J Eur Acad Dermatol Venereol ; 18(6): 713-5, 2004 Nov.
Article En | MEDLINE | ID: mdl-15482305

A 45-year-old woman presented with fever, generalized skin lesions and multiple lymphadenopathies. In her past history she had had six courses of cyclophosphamide and cisplatin combination chemotherapy 7 years ago because of an ovarian carcinoma. We found pancytopenia in the peripheral blood examination. Skin biopsy showed diffuse subcutaneous infiltration reminiscent of panniculitis but composed of malignant lymphoid cells that were of T lineage. Bone marrow biopsy showed normocellular myeloid tissue with abundant haemophagocytic macrophages. Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome was diagnosed. This is the first case reported of subcutaneous panniculitis-like lymphoma occurring secondary to chemotherapy.


Antineoplastic Combined Chemotherapy Protocols/adverse effects , Blood Coagulation Disorders/chemically induced , Lymphoma, T-Cell, Cutaneous/chemically induced , Panniculitis/chemically induced , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Female , Humans , Middle Aged , Ovarian Neoplasms/drug therapy
16.
J Chemother ; 16(3): 288-92, 2004 Jun.
Article En | MEDLINE | ID: mdl-15330327

The purpose of this study was to evaluate the impact of granulocyte-colony stimulating factor (G-CSF) on the therapy for febrile neutropenia (FN). Our patient population differed significantly from those of previous studies as no patients received antimicrobial or CSF prophylaxis before randomization and all were solid tumor patients. When the diagnosis of FN was established, patients were started on intravenous meropenem 1 g every 8 hours and randomly assigned to receive G-CSF (5 microg/kg body weight per day subcutaneously) or not. Twenty-eight patients with 30 FN episodes received G-CSF and 25 patients with 30 FN episodes did not receive G-CSF according to randomization. The time to resolution of fever, recovery of neutrophil count over 1000/mm3, duration of hospitalization, need for erythrocyte and platelet transfusion and mortality rate were similar in both study groups. Side effects of therapy were mild. These results provide preliminary evidence that G-CSF administration, in addition to effective antibiotic therapy as treatment of febrile neutropenic patients with solid tumor, does not help improve infection-related morbidity and mortality.


Fever/drug therapy , Granulocyte Colony-Stimulating Factor/administration & dosage , Neutropenia/drug therapy , Thienamycins/administration & dosage , Adolescent , Adult , Aged , Comorbidity , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Fever/diagnosis , Fever/mortality , Follow-Up Studies , Humans , Meropenem , Middle Aged , Neoplasms/diagnosis , Neoplasms/drug therapy , Neoplasms/mortality , Neutropenia/diagnosis , Neutropenia/mortality , Probability , Prospective Studies , Reference Values , Risk Assessment , Severity of Illness Index , Statistics, Nonparametric , Survival Rate , Treatment Outcome
17.
J Thromb Haemost ; 2(8): 1266-71, 2004 Aug.
Article En | MEDLINE | ID: mdl-15304029

BACKGROUND: Small cell lung cancer (SCLC) is a chemotherapy-responsive tumor type but most patients ultimately experience disease progression. SCLC is associated with alterations in the coagulation system. The present randomized clinical trial (RCT) was designed to determine whether addition of low-molecular-weight heparin (LMWH) to combination chemotherapy (CT) would improve SCLC outcome compared with CT alone. METHODS: Combination CT consisted of cyclophosphamide, epirubicine and vincristine (CEV) given at 3-weekly intervals for six cycles. Eighty-four patients were randomized to receive either CT alone (n = 42) or CT plus LMWH (n = 42). LMWH consisted of dalteparin given at a dose of 5000 U once daily during the 18 weeks of CT. Results Overall tumor response rates were 42.5% with CT alone and 69.2% with CT plus LMWH (P = 0.07). Median progression-free survival was 6.0 months with CT alone and 10.0 months with CT plus LMWH (P = 0.01). Median overall survival was 8.0 months with CT alone and 13.0 months with CT plus LMWH (P = 0.01). Similar improvement in survival with LMWH treatment occurred in patients with both limited and extensive disease stages. The risk of death in the CT + LMWH group relative to that in the CT group was 0.56 (95% confidence interval 0.30, 0.86) (P = 0.012 by log rank test). Toxicity from the experimental treatment was minimal and there were no treatment-related deaths. CONCLUSIONS: These results support the concept that anticoagulants, and particularly LMWH, may improve clinical outcomes in SCLC. Further clinical trials of this relatively non-toxic treatment approach are indicated.


Anticoagulants/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/drug therapy , Heparin, Low-Molecular-Weight/therapeutic use , Lung Neoplasms/drug therapy , Adult , Aged , Cyclophosphamide/administration & dosage , Dalteparin/administration & dosage , Disease Progression , Disease-Free Survival , Epirubicin/administration & dosage , Female , Humans , Male , Middle Aged , Time Factors , Treatment Outcome , Vincristine/administration & dosage
18.
Gynecol Obstet Invest ; 52(3): 168-72, 2001.
Article En | MEDLINE | ID: mdl-11598358

The purpose of this study was to investigate the occurrence rate of APC resistance (APC-R) with severe preeclampsia in Turkish women. Thirty-two consecutive women having severe preeclampsia were included in the study. Thirty-two healthy pregnant women served as the control group. APC-R assays were performed in the third trimester of pregnancy, and 3 and 9 months after delivery. APC-R was demonstrated in the third trimester, 3 months and 9 months after delivery in 27 (84.4%), 23 (71.9%) and 5 (15.6%) of 32 preeclamptic patients, respectively. APC-R rates were significantly higher in preeclamptic group than in normal pregnant women in the third trimester of pregnancy (p < 0.05). Decreased mean APC activity and also increased APC-R rate was still persisting in preeclamptic group for 3 months after delivery. Nine months after delivery, the mean APC activity and also APC-R rates approached to the normal pregnant women; however, there was a significant difference between both groups (p < 0.05). Our results indicate that acquired APC-R may be a contributory factor in the pathogenesis of preeclampsia.


Activated Protein C Resistance/complications , Pre-Eclampsia/etiology , Activated Protein C Resistance/blood , Adult , Antithrombin III/metabolism , Blood Coagulation Tests , Female , Humans , Pre-Eclampsia/blood , Pregnancy , Protein C/metabolism , Protein C/physiology , Protein S/metabolism , Protein S/physiology , Turkey
19.
Urol Int ; 67(2): 175-7, 2001.
Article En | MEDLINE | ID: mdl-11490218

A case history is reported here in which leukocytosis, thrombocytosis and hypercalcemia associated with rapidly relapsing squamous cell carcinoma (SCC) of the renal pelvis were observed. In a 58-year-old man, SCC of the renal pelvis was documented during nephrolithotomy, and right nephrectomy was performed. Local relapse of the tumor occurred rapidly in 2 months' time and hypercalcemia, leukocytosis and thrombocytosis worsened in accordance with tumor volume. Cranial computerized tomography (CT), thorax CT and bone scintigraphy were negative for metastasis. The serum parathyroid hormone level was 28 pg/ml (normal 9- 55 pg/ml). To disclose leukocytosis and thrombocytosis, peripheral smear and bone marrow aspiration were performed and no pathologic finding regarding any hematologic disorder was found; the samples were also BCR-ABL negative and Philadelphia chromosome negative. Production of several factors by tumor cells may be responsible for this paraneoplastic syndrome. The association of SCC of the renal pelvis with this triple paraneoplastic syndrome is an extremely rare occurrence.


Carcinoma, Squamous Cell/diagnosis , Hypercalcemia/diagnosis , Kidney Neoplasms/diagnosis , Kidney Pelvis , Leukocytosis/diagnosis , Neoplasm Recurrence, Local/diagnosis , Paraneoplastic Syndromes/diagnosis , Thrombocytosis/diagnosis , Humans , Male , Middle Aged , Time Factors
20.
Jpn J Clin Oncol ; 31(2): 86-8, 2001 Feb.
Article En | MEDLINE | ID: mdl-11302348

Granulocytic sarcoma is an extramedullary tumor associated with acute or chronic leukemias or myeloproliferative disorders. Rarely, the tumor may be seen before the diagnosis of leukemia. Symptomatic facial nerve paralysis and spinal cord invasion by granulocytic sarcomas are also relatively uncommon. We present here a 17-year-old-female patient who had facial nerve paralysis and paraplegia due to granulocytic sarcoma as the presenting symptoms of acute myeloid leukemia.


Facial Paralysis/etiology , Leukemia, Myeloid/complications , Paraplegia/etiology , Acute Disease , Adolescent , Female , Humans , Leukemia, Myeloid/pathology , Magnetic Resonance Imaging , Spinal Cord Compression/pathology
...